Erudio Healtherudio.com
Sponsor
Intergroupe Francophone de Cancerologie Thoracique trials: what clinicians said in public
An HCP commentary report on 1 clinical trial sponsored by Intergroupe Francophone de Cancerologie Thoracique: DIAL. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 4 more trials with public commentary and no report yet.
Listed by lead sponsor as registered on ClinicalTrials.gov (Intergroupe Francophone de Cancerologie Thoracique). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| DIAL NCT05255302 · Intergroupe Francophone de Cancerologie Thoracique | metastatic NSCLC | Phase 2/Phase 3 | 29 | 15 | Focused | Oct 28, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| ENCO-BRAF NCT04526782 · Intergroupe Francophone de Cancerologie Thoracique DeepView → | BRAF V600E-mutant metastatic non-small cell lung cancer | Phase 2 | Deep | View | |||
| DICIPLE NCT03469960 · Intergroupe Francophone de Cancerologie Thoracique StandardView → | PD-L1-positive stage IV non-small cell lung cancer | Phase 3 | Standard | View | |||
| IFCT-0302 NCT00198341 · Intergroupe Francophone de Cancerologie Thoracique FocusedView → | completely resected non-small-cell lung cancer | Not applicable | Focused | View | |||
| R2D2 NCT03845270 · Intergroupe Francophone de Cancerologie Thoracique FocusedView → | advanced non-small cell lung cancer harboring HER2 mutations | Phase 2 | Focused | View | |||